These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9080424)

  • 1. Presymptomatic revelation of experimental parkinsonism.
    Bezard E; Boraud T; Bioulac B; Gross CE
    Neuroreport; 1997 Jan; 8(2):435-8. PubMed ID: 9080424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.
    Bezard E; Boraud T; Bioulac B; Gross CE
    Neuroscience; 1997 Nov; 81(2):399-404. PubMed ID: 9300430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamatergic compensatory mechanisms in experimental parkinsonism.
    Bezard E; Bioulac B; Gross CE
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):609-23. PubMed ID: 9682276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
    Bergman H; Wichmann T; DeLong MR
    Science; 1990 Sep; 249(4975):1436-8. PubMed ID: 2402638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
    Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
    Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
    J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
    Kanagaraj N; Beiping H; Dheen ST; Tay SS
    Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
    Masilamoni GJ; Groover O; Smith Y
    Neurobiol Dis; 2017 Apr; 100():9-18. PubMed ID: 28042095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
    Bezard E; Boraud T; Bioulac B; Gross CE
    Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease.
    Vezoli J; Fifel K; Leviel V; Dehay C; Kennedy H; Cooper HM; Gronfier C; Procyk E
    PLoS One; 2011; 6(8):e23952. PubMed ID: 21887350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.
    Pifl C; Hornykiewicz O
    Neurochem Int; 2006 Oct; 49(5):519-24. PubMed ID: 16698121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
    Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
    Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
    Kunikowska G; Jenner P
    Brain Res; 2003 Apr; 968(2):206-18. PubMed ID: 12663090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.
    Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Belzunegui S; Izal-Azcárate A; López B; Marcilla I; Luquin MR
    J Neuropathol Exp Neurol; 2009 Jan; 68(1):26-36. PubMed ID: 19104449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.